Drug Approval | December 26, 2023
Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment
US FDA approval based on NEURO-TTRansform Phase III results
US FDA approval based on NEURO-TTRansform Phase III results
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The inspection of the facility conducted from August 7 to August 11, 2023
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Subscribe To Our Newsletter & Stay Updated
